US Stock MarketDetailed Quotes

CADL Candel Therapeutics

Watchlist
  • 8.550
  • +0.260+3.14%
Close Feb 12 16:00 ET
380.27MMarket Cap-4.94P/E (TTM)

About Candel Therapeutics Company

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Company Profile

SymbolCADL
Company NameCandel Therapeutics
Listing DateJul 27, 2021
Issue Price8.00
Founded2002
CEODr. Paul Peter Tak, M.D.,PhD
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address117 Kendrick Street,Suite 450
CityNeedham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02494
Phone1-617-916-5445

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Paul Peter Tak, M.D.,PhD
  • President, Chief Executive Officer and Director
  • 1.48M
  • Charles Schoch
  • Interim Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Francesca Barone, M.D.,PhD
  • Chief Scienctific Officer
  • 706.88K
  • Seshu Tyagarajan, PhD,R.A.C.
  • Chief Technical and Development Officer
  • --
  • Dr. William Garrett Nichols, M.A.,M.D.
  • Chief Medical Officer
  • --
  • Paul B. Manning
  • Chairman of the Board
  • 83.19K
  • Dr. Estuardo Aguilar-Cordova, M.D.,PhD
  • Director
  • 48.19K
  • Renee M. Gaeta
  • Independent Director
  • 55.69K
  • Joseph C. Papa
  • Independent Director
  • 58.19K
  • Dr. Nicoletta Loggia, PhD,R.Ph.
  • Independent Director
  • 52.76K
  • Dr. Diem Nguyen, M.B.A.,PhD
  • Independent Director
  • 60.69K
  • Christopher Martell
  • Independent Director
  • 67.19K
  • Dr. Edward J. Benz, Jr,M.D.
  • Independent Director
  • 56.19K
  • Dr. Gary J. Nabel, M.D.,PhD
  • Independent Director
  • 52.19K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More